Institute for Translational Oncology Research (ITOR)

ITOR Vision

To be an international destination center that develops and delivers innovative and personalized  cancer  therapies.

ITOR is a major pillar of translational cancer research at Prisma Health. The efforts of ITOR include a phase I Clinical Research Unit, a Biorepository Services platform, and proteomics & genomics capabilities.

ITOR advances cancer care on multiple levels, facilitating pioneering research as well as clinical care delivery. ITOR is committed to “translational” medicine, which is a branch of medical research that forges a direct link between basic research and patient care. In the case of drug therapies, translational medicine refers to the “translation” of basic research into beneficial drug treatments for patients.

ITOR focuses on discovering and developing drugs that help people who have cancer.

Our Location

ITOR is embedded onsite at
Greenville Memorial Medical Campus
701 Grove Road
Greenville, SC 29605

ITOR Missions

  • Achieve the most efficient translation of basic science into the clinical investigation of cancer care
  • Discover and develop clinically meaningful molecular and genomic markers with prognostic and predictive capabilities
  • Create an environment in which to educate and train medical professionals in translational and personalized medicine

While modest advances continue to be made in the prevention, diagnosis and treatment of cancers, in order to effectively and rapidly transfer basic science data and discovery into meaningful clinical benefit, it is ITOR’s belief that the existing culture of cancer research must place more value and emphasis on translational and clinical research.

As such, ITOR aspires to be one of the country’s leaders in the fulfillment of an unprecedented translational research model of the future – through its unique vision, capabilities, consortia of expert partners, and focus on diagnostic and therapeutic treatments of cancer.

An ultimate goal is to help develop breakthroughs in rapid drug development and accompanying diagnostic discovery through  new cutting-edge business models and emerging technologies – including genomic profiling of cancer tumors and the design of clinical trials utilizing known targets that are expressed, versus disease specific, in order to achieve true personalized medicine – ultimately advancing cancer care for patients.

ITOR’s commitment to this proposition will be achieved in part through translational research initiatives undertaken in partnership with fellow collaborators.

ITOR Leadership

Jeff Edenfield, MD
Medical Director

Ki Young Chung, MD
Associate Medical Director

Larry Gluck, MD
Medical Director – Prisma Health Cancer Institute

Julie Work (2)

Julie C. Martin, DNP, AOCN, NP  
Director of Cancer Research
Phone: (864) 455-3667
Fax: (864) 455-3618


Jan Kueber, BSN, OCN, MBA
Clinical Research Unit Manager (CRU)
Phone: (864) 455-3774
Fax: (864) 455-3618

CRU Research Nurses

Lisa Johnson, RN, BSN
Phone: (864) 455-3735
Fax: (864) 455-3618

Fiona Davidson, RN, BSN
Phone: (864) 455-3737
Fax: (864) 455.3618

Specific Areas of Interest

If you are a patient interested in clinical trials OR a physician who would like to refer a patient, please contact Lisa Johnson, RN, BSN or Fiona Davidson, RN.

If you would like information about ITOR Biorepository Services, please contact Lauren Baber, BSN, RN at (864) 455-1459 or email